Contact us Demo our platform

Metabolon @

Digestive Disease Week 2025

Dates: May 3–6, 2025 | Exhibit Dates: May 4–6, 2025
Location: San Diego, California & Online
Visit the Official Event Website

Join Metabolon at DDW 2025

Metabolon is attending Digestive Disease Week® (DDW) 2025, the world’s leading event for gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. This event brings together top physicians, researchers, and industry professionals to share the latest discoveries and advancements in digestive health.

About Digestive Disease Week 2025

DDW is the largest global gathering of experts in digestive disease research and clinical practice. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW showcases over 5,000 abstracts and hundreds of expert-led sessions on cutting-edge advancements in the field.

This event provides unparalleled opportunities for education, networking, and innovation, making it a must-attend conference for professionals researching digestive diseases and for investigators in pursuit of novel discoveries that may lead to new drugs and therapies utilizing the gut-microbiome.

Scientific Themes and Program Highlights

DDW 2025 will feature breakthrough research, clinical advancements, and emerging technologies across multiple disciplines. Attendees can expect:

  • Gastrointestinal Disorders – Innovations in diagnostics and treatment strategies.
  • Liver Disease Research – Advances in hepatology, including NAFLD/NASH and liver transplantation.
  • Endoscopic Technologies – New approaches in endoscopic procedures and techniques.
  • Surgical Innovations – The latest developments in gastrointestinal surgery.
  • Microbiome & Metabolomics – The role of gut microbiota and metabolism in health and disease.

View the Preliminary Program

Why Metabolon is Attending DDW 2025

Metabolomics is transforming gastroenterology and digestive disease research by providing deeper insights into metabolic pathways, gut-microbiome interactions, gut-brain axis associations, and wider disease mechanisms. As the leader in metabolomics-driven discovery, Metabolon provides expert services to support fast, accurate, and actionable multiomic insights that drive innovation in digestive health.

At DDW 2025, Metabolon will highlight how our metabolomics and bioinformatics solutions are enabling breakthroughs in gastroenterology by:

  • Delivering best-in-class metabolic and microbiome profiling and advanced bioinformatics solutions, enabling researchers to explore the functional impact of gut microbial activity.
  • Integrating metabolomics and metagenomics data for truly scalable insights within Metabolon’s Integrated Bioinformatics Platform, maximizing study power, biological relevance, and research outcomes.
  • Enhancing understanding of microbiome-metabolome interactions in inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colorectal cancer, liver disease, and many more metabolic disorders by characterizing metabolic shifts associated with gut microbial dysbiosis.
  • Identifying novel biomarkers for gastrointestinal and liver disorders, supporting early detection, disease progression monitoring, and precision medicine strategies.
  • Driving clinical and translational research by providing metabolomics insights that help validate drug targets, predict treatment response, and uncover novel therapeutic pathways.
  • Supporting large-scale gut microbiome studies for population health research, offering deeper insight into the metabolic signatures linked to gut microbiota composition, dietary influences, and disease susceptibility.

By integrating metabolomics with microbiome and genomic research, Metabolon is powering the next generation of precision medicine approaches in gastroenterology.

Visit us at DDW 2025 to learn how our unparalleled coverage, quantitation, and interpretation of metabolic data can advance your research.

DDW 2025 will host leading experts presenting groundbreaking research and clinical insights. Stay tuned for the official speaker lineup and session details.

View All Speakers and Sessions

Where to Find Metabolon at DDW 2025

Visit our team of experts at booth #4559 in the exhibit hall. To schedule a meeting with our metabolomics and bioinformatics specialists, please use the contact form on this page.

Register for DDW 2025
Attendee Guide
Program Planning Resources
Meeting Planner
Scientific Sessions
Abstracts and Poster Hall
Networking Events
Exhibit Hall Details

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.